<DOC>
	<DOCNO>NCT01600274</DOCNO>
	<brief_summary>- Characterisation relative bioavailability Diena ( Test ) comparison Valette® ( Reference ) single dose administration fast condition - Assessment bioequivalence Test vs. Reference single dose administration fast condition , determine use area concentration time curve AUC0-tlast maximum concentration Cmax obtain ethinylestradiol ( EE ) dienogest ( DNG ) - Descriptive characterisation safety tolerability investigational product study population</brief_summary>
	<brief_title>Bioavailability Study With Oral Single Dose Administration Ethinylestradiol Dienogest</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<criteria>1. sex : female 2. ethnic origin : Caucasian 3. age : 18 55 year , inclusive 4. bodymass index ( BMI ) : 19 kg/m² less 27 kg/m² 5. good state health 6. nonsmoker exsmoker least 6 month 7. write informed consent , inform benefit potential risk trial , well detail insurance take cover subject 's participating study Subjects include match follow exclusion criterion : Safety concern 1. exist cardiac haematological disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 2. exist hepatic and/or renal disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 3. exist gastrointestinal disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 4. history relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 5. pathological ECG ( 12 standard lead ) might interfere safety active ingredient 6. know allergic reaction active ingredient use constituent pharmaceutical preparation 7. subject severe allergy multiple drug allergy 8. systolic blood pressure &gt; 160 mmHg 9. diastolic blood pressure &gt; 90 mmHg 10. heart rate &lt; 45 &gt; 100 bpm 11. laboratory value normal range unless deviation normal judge relevant study investigator 12. positive antiHIVtest , HBsAGtest antiHCVtest 13. presence history venous arterial thrombosis ( e.g . deep venous thrombosis , pulmonary embolism , myocardial infarction prodromal condition ( e.g . transient ischaemic attack , angina pectoris ) ) , predisposition venous arterial thrombosis ( e.g . APCresistance , antithrombinIIIdeficiency , protein C deficiency , protein S deficiency thrombogene coagulopathy , heart valve disorder thrombogene cardiac dysrhythmias ) 14. presence history liver tumours know suspected sexhormone influence malignancy ( e.g . breast endometrium ) 15. unclarified vaginal bleeding amenorrhoe 16. subject fructose galactose intolerance , deficiency lactase , saccharaseisomaltase malabsortion glucose/galactose Lack suitability trial 17. acute chronic disease could affect absorption metabolism 18. history current drug alcohol dependence 19. regular intake alcoholic food beverage ≥ 20 g per day 20. subject diet could affect pharmacokinetics active ingredient 21. regular intake caffeine contain food beverage ≥ 500 mg per day 22. blood donation blood loss 400 ml within last two month prior individual enrolment subject 23. participation clinical trial last two month prior individual enrolment subject 24. regular treatment systemically available medication ( except usual replacement therapy Lthyroxine ) 25. subject , report frequent occurrence migraine attack 26. use hormonal preparation within 6 week ( oral , transdermal , vaginal ) , 2 month ( intramuscularly administer depot preparation use per month ) 6 month ( intramuscularly administer depot preparation use per 3 month ) prestudy examination For female subject childbearing potential : 27. positive pregnancy test prestudy examination 28. pregnant lactate woman 29. female subject agree apply adequate nonhormonal highly effective contraceptive method define Note Guidance NonClinical Safety Studies Conduct Human Clinical Trials Pharmaceuticals ( CPMP/ICH/286/95 , modification ) , November 2000 Administrative reason 30. subject suspect know follow instruction 31. subject unable understand write verbal instruction , particular regard risk inconvenience expose participation study The exclusion criterion choose assure subject specific risk administration investigate medicinal product subject condition , may impact pharmacokinetic parameter , include .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>